Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study.

Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study.

Item
http://www.wikidata.org/entity/Q33547514
Association of rs780094 in GCKR with metabolic traits and incident diabetes and cardiovascular disease: the ARIC StudyThe hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic ratsLess but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level.Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetesA genome-wide association meta-analysis of circulating sex hormone-binding globulin reveals multiple Loci implicated in sex steroid hormone regulationVariant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescentsPolymorphisms in the GCKR are associated with serum lipid traits, the risk of coronary artery disease and ischemic stroke.Metabolite profiling reveals normal metabolic control in carriers of mutations in the glucokinase gene (MODY2)Polymorphisms in Four Genes (KCNQ1 rs151290, KLF14 rs972283, GCKR rs780094 and MTNR1B rs10830963) and Their Correlation with Type 2 Diabetes Mellitus in Han Chinese in Henan Province, ChinaA genome-wide association study of multiple longitudinal traits with related subjects.Effects of a glucokinase activator on hepatic intermediary metabolism: study with 13C-isotopomer-based metabolomics.Lack of associations of ten candidate coronary heart disease risk genetic variants and subclinical atherosclerosis in four US populations: the Population Architecture using Genomics and Epidemiology (PAGE) study.Association of ketone body levels with hyperglycemia and type 2 diabetes in 9,398 Finnish men.Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes.Molecular targeting of the GK-GKRP pathway in diabetes.HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults.
P2860

Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study.

Item
http://www.wikidata.org/entity/Q33547514
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Glucokinase-activating GCKR po ...... d Cardiovascular Health Study.
@ast
Glucokinase-activating GCKR po ...... d Cardiovascular Health Study.
@en
Glucokinase-activating GCKR po ...... d Cardiovascular Health Study.
@nl
type
label
Glucokinase-activating GCKR po ...... d Cardiovascular Health Study.
@ast
Glucokinase-activating GCKR po ...... d Cardiovascular Health Study.
@en
Glucokinase-activating GCKR po ...... d Cardiovascular Health Study.
@nl
prefLabel
Glucokinase-activating GCKR po ...... d Cardiovascular Health Study.
@ast
Glucokinase-activating GCKR po ...... d Cardiovascular Health Study.
@en
Glucokinase-activating GCKR po ...... d Cardiovascular Health Study.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Glucokinase-activating GCKR po ...... d Cardiovascular Health Study.
@en
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921